Monoclonal antibody M195

Drug Profile

Monoclonal antibody M195

Alternative Names: Aclizumab; Anti-CD33 monoclonal antibody M195; KB 195; SMART M195; SMART M195 antibody; Zamyl™

Latest Information Update: 11 Sep 2003

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nippon Organon; Nonindustrial source; PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myeloid leukaemia; Preleukaemia

Most Recent Events

  • 25 Aug 2002 Discontinued - Phase-II for Preleukaemia (unspecified route)
  • 25 Aug 2002 Discontinued - Phase-III for Acute myeloid leukaemia in USA (unspecified route)
  • 25 Aug 2002 Discontinued - Phase-II for Acute promyelocytic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top